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Abstract
Background: The percentage of mammographic dense tissue (PD) defined by pixel value threshold is a well-
established risk factor for breast cancer. Recently there has been some evidence to suggest that an increased
threshold based on visual assessment could improve risk prediction. It is unknown, however, whether this also
applies to volumetric density using digital raw mammograms.
Method: Two case-control studies nested within a screening cohort (ages of participants 46–73 years) from
Manchester UK were used. In the first study (317 cases and 947 controls) cases were detected at the first screen;
whereas in the second study (318 cases and 935 controls), cases were diagnosed after the initial mammogram.
Volpara software was used to estimate dense tissue height at each pixel point, and from these, volumetric and
area-based PD were computed at a range of thresholds. Volumetric and area-based PDs were evaluated using
conditional logistic regression, and their predictive ability was assessed using the Akaike information criterion
(AIC) and matched concordance index (mC).
Results: The best performing volumetric PD was based on a threshold of 5 mm of dense tissue height (which we
refer to as VPD5), and the best areal PD was at a threshold level of 6 mm (which we refer to as APD6), using pooled
data and in both studies separately. VPD5 showed a modest improvement in prediction performance compared to the
original volumetric PD by Volpara with ΔAIC = 5.90 for the pooled data. APD6, on the other hand, shows much
stronger evidence for better prediction performance, with ΔAIC = 14.52 for the pooled data, and mC increased
slightly from 0.567 to 0.577.
Conclusion: These results suggest that imposing a 5 mm threshold on dense tissue height for volumetric PD
could result in better prediction of cancer risk. There is stronger evidence that area-based density with a 6 mm
threshold gives better prediction than the original volumetric density metric.
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Background
The percentage of mammographic density (PD) that ap-
pears white in a mammogram and reflects the relative
amount of fibroglandular tissue in the breast is a
well-established risk factor for breast cancer [1]. PD is
the most predictive marker of breast cancer for women
after familial causes and polygenic markers when ad-
justed for age and body mass index (BMI) [2]. For
area-based PD, fibroglandular and fatty tissues may be
segmented by thresholding, and this is usually achieved
by a semi-automatic approach where the threshold is
chosen by the investigator using software such as Cumu-
lus [3]. There has been recent evidence that increasing
the conventional brightness threshold might better pre-
dict breast cancer risk: this has been demonstrated in
Korean women with “for presentation” (processed)
full-field digital mammograms [4, 5], and Australian
women with digitised film mammograms [6].
In addition to subjective visual assessment, another
approach for PD estimation using digital mammograms
is volumetric density measurement via a fully automated
system. Commercial volumetric PD systems including
Volpara [7] and Quantra [8] have shown good agree-
ment with semi-automated thresholding and an associ-
ation with risk of breast cancer [9]. In Volpara, pixel
values are calibrated so that the height (amount) of dense
tissue at any given point in a mammogram can be esti-
mated, and based on these heights and the estimated
breast volume, volumetric density can be determined. By
default all dense tissue, regardless of the height at any
pixel position, is included to compute the dense volume.
However, there appear to be no published studies that
have looked at whether applying a threshold to dense tis-
sue heights, effectively excluding some less dense tissue as
well as possibly thin sheets or strands of tissue that have
similar attenuation coefficients to glandular tissue, could
result in better prediction of breast cancer risk.
The aim of this paper is to investigate whether volu-
metric or area-based PD can be adjusted by varying
dense tissue height thresholds so as to better predict
breast cancer risk. In previous research [4–6] threshold-
ing was based on pixel brightness from visual assess-
ment, whereas here thresholds on dense tissue heights
from volumetric density estimation are used. This allows
the calculation of breast density and the application of a
chosen threshold to be fully automated (i.e. without
manual visual assessment) on digital mammograms. In
addition, our thresholding analysis is based on Western
women with digital raw mammograms, and to our
knowledge this has not been previously examined. An
important benefit of using raw images compared to
processed images is that it could reduce the discrepan-
cies between different machines due to manufacturers’
proprietary processing algorithms.
Methods
Setting and study design
Two case-control studies were designed as a part of the
Predicting Risk Of breast Cancer At Screening (PRO-
CAS) cohort, in Manchester, UK [10]. The first
case-control study had 317 cases and 947 controls while
the second had 318 cases and 935 controls. A detailed
description of the data in the two studies has been re-
ported previously [11, 12] (the sample used for analysis
differs slightly; see Appendix). Briefly, in the first
case-control study, cases comprised women with cancer
detected at first screen on entry into the PROCAS cohort,
and we refer to this dataset as study 1. As in our previous
study [11], the craniocaudal (CC) views of the contralat-
eral breast for cases and the left breast for controls were
used. In the second case-control study, each woman
had a normal screening mammogram (no cancer de-
tected) on entry into the PROCAS cohort, but an inter-
val or screen-detected cancer arose subsequently, and
we refer to this dataset as study 2. Similar to our previ-
ous study [11], the CC views of the contralateral breast
for cases and the same side for controls were used. The
mammograms were obtained on average three years prior
to diagnosis of breast cancer and from the same cohort as
study 1. In both studies women were matched approxi-
mately 3:1 (controls vs cases) by age, BMI, hormone re-
placement therapy (HRT) use and menopausal status.
Mammograms
All digital raw (“for processing”) mammograms were ac-
quired using a GE Senographe system. Volumetric dens-
ity, especially the height of dense tissue at each point in
the mammogram, was assessed using Volpara 1.5.2 (Vol-
para Health Technologies, Wellington, New Zealand).
Density measurements
One output from the Volpara software is a “density
map” - it contains data on dense tissue height at every
point in the mammogram, based on an analysis of pixel
values and imaging parameters. Whilst no thresholding
is applied in the default output of the software, different
threshold values can be tested such that only densities
with a height greater than a certain threshold value are
included for computing total dense volume. For in-
stance, when a threshold level of 5 mm is used, only
those density heights greater than 5 mm are employed
to calculate the total dense volume. We refer to this ap-
proach to computing PD as volumetric PD (VPD) in this
paper, and specifically the default volumetric PD output
by Volpara as VPD0 (i.e. the threshold level is 0 mm).
The aforementined approach focuses on percentage of
volumetric density as the end point. An alternative ap-
proach is to look at the two-dimensional area of dense
tissue within the breast: here this is defined as the
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number of pixels with dense tissue heights greater than
a chosen threshold. This is then divided by the total num-
ber of pixels in the breast and expressed as a percentage
area of dense tissue. As with the volumetric approach, a
series of threshold values can be considered. We refer to
this as areal PD (APD) in this paper. Note that although
APD is an areal measurement, the underlying basis is still
volumetric density because dense tissue height (or effect-
ively volume) at each point in the mammogram was used.
Statistical analysis
PDs at various threshold levels, ranging from 0 to
25 mm, were evaluated using conditional logistic re-
gression, based on the pooled data (study 1 and 2 com-
bined) and on study 1 and 2 separately. The Akaike
information criterion (AIC) and matched concordance
index (mC) [13] were calculated to measure prediction
performance. AIC is a likelihood-based statistic derived
from the information theory and is a well-established
method for model comparison [14]. A lower AIC value in-
dicates better model performance. mC is a modification of
the concordance index (or area under the receiving oper-
ator characteristic curve, AUC) for matched case-control
studies, and gives an average concordance index within
matched groups. Bootstrap with 10,000 replications was
used to assess whether the difference in mC from dif-
ferent models was statistically significant. All p values
are two-sided.
Since biologic phenotypes between screen-detected
and interval cancers are different, a further analysis was
conducted to test whether there was any significant dif-
ference between screen-detected and interval breast
cancers. In addition to the fixed threshold level for every
woman, sensitivity analysis was conducted by varying
the threshold according to a woman’s characteristics
based on a linear model, using age, BMI, thickness and
total volume of the breast to explore the difference be-
tween varying and fixed thresholds.
Results
Study characteristics
The demographic characteristics of the women in both
studies are presented in Table 1. Age, BMI, menopausal
status and HRT use were well-matched between cases
and controls in both studies. The median 10-year
Tyrer-Cuzick score was higher for cases than controls.
The majority of women never used HRT, were postmen-
opausal, parous and ethnically white.
Results for pooled data
Conditional logistic regression was used to evaluate
model fit at various threshold levels using both datasets
combined. The resulting AICs for VPDs and APDs are
presented in Fig. 1. It can be seen that both VPDs and
APDs have their lowest value at the 5–6 mm threshold
level, where improvement over original volumetric PD
(i.e. VPD0) is clear. APD at the threshold of 6 mm
achieved the lowest AIC overall.
Distributions of VPDs and APDs at different threshold
levels (0–12 mm) were inspected using box plots as
shown in Fig. 2. Correlations between VPD0 and the best
performing VPD and APD - VPD5 and APD6, respect-
ively, are presented in Fig. 3. The Spearman statistic was
0.95 for correlation between VPD0 and VPD5, 0.90 for
correlation between VPD0 and APD6 and 0.98 for
correlation between VPD5 and APD6.
Table 2 compares the results of five modelling schemes
using different sets of risk predictors: (1) VPD0; (2) volu-
metric PD at 5 mm (VPD5); (3) areal PD at 6 mm
(APD6); (4) VPD0 + VPD5 and (5) VPD0 + APD6. Each
modelling scheme was denoted as M1 to M5, respect-
ively. M1 represents the original volumetric PD esti-
mated by Volpara (i.e. zero or no thresholding) and its
model performance was used as the baseline for com-
parison with other models. M1 was then compared with
M2 and M3 which were based on 5 mm and 6 mm
thresholds for VPD and APD, respectively, as the best fit
was found at these levels of threshold as shown above.
M4 was used to explore whether the prediction perform-
ance for VPD5 can be further improved by adding the
original Volpara estimate (VPD0); similarly, M5 was
used to explore whether VPD0 adds information once
having already controlled for APD6. The model with the
lowest AIC indicates the best modelling approach for
breast cancer risk prediction.
As seen in Table 2, M3, the model using only APD at
6 mm, was the best performing in terms of AIC.
Compared to M1, the model using original volumetric
PD (VPD0), the AIC was substantially improved with
ΔAIC = 14.52. mC also increased slightly from M1 to
M3 (from 0.567 to 0.577); whilst the change in mC was
small it was still statistically significant (p value = 0.019).
To show the effect of thresholding, an example is
presented in Fig. 4, which shows thresholding of a mam-
mogram at different levels.
Results for study 1 and 2
Following analysis based on pooled data, a series of con-
ditional logistic regression models for study 1 (cancers
detected at the first screen on entry into the PROCAS
cohort) and study 2 (cancers diagnosed subsequently)
were explored, as well as screen-detected vs interval can-
cers within study 2. Similarly, five modelling schemes
(M1–M5) were tested and the results are presented in
Tables 3 and 4.
As with the pooled data, M3, the model using only
APD at 6 mm, was the preferred model in terms of AIC
in study 1 (Table 3). Compared to M1, there was modest
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improvement in the AIC (ΔAIC = 5.25). Statistically,
however, there was little difference in mC between M1
and M3 (p value = 0.60). Adding VPD0 to APD6 (M5)
failed to improve model performance in terms of the AIC.
In study 2, M3 was again the best model in terms of
the AIC (Table 4). Compared to VPD0 (M1), APD6
(M3) was considerably superior in terms of the AIC
(ΔAIC = 9.36). mC for M3 was also significantly higher
than for M1 (p value <0.001). VPD0 did not add
statistically significant information after controlling for
APD6 (M5 vs M3, p value = 0.24). Indeed, it can be
shown that similar to the result shown in Fig. 1, APD6
(M3) was a better predictor than volumetric or other
areal PDs at different thresholds both in studies 1 and 2.
A series of likelihood-ratio tests were performed on
the aforementioned models to test whether there was
any significant difference between screen-detected and
interval cancers within study 2. The interaction term
Table 1 Demographics of Study 1 (cancers detected at first screen on entry to the PROCAS study) and Study 2 (cancers detected at
a subsequent screen or between screening rounds)
Study 1 Study 2
Controls Cases p value Controls Cases p value
Number (%) Number (%) Number (%) Number (%)
Age at consent (years) 0.9997 0.9997
< 50 53 (6) 19 (6) 46 (5) 16 (5)
50–54 242 (26) 79 (25) 194 (21) 64 (20)
55–59 153 (16) 52 (16) 164 (18) 58 (18)
60–64 229 (24) 77 (24) 286 (31) 96 (30)
65–69 196 (21) 66 (21) 198 (21) 68 (21)
70+ 74 (8) 24 (8) 47 (5) 16 (5)
HRT use 0.0778 0.9320
Unknown 14 (1) 9 (3) 23 (2) 6 (2)
Never 568 (60) 208 (66) 475 (51) 166 (52)
Previous 315 (33) 83 (26) 332 (36) 110 (35)
Current 50 (5) 17 (5) 105 (11) 36 (11)
BMI (kg/m2) 0.9954 0.9389
Unknown 1 (0) 1 (0)
< 25 332 (35) 112 (35) 335 (36) 117 (37)
25–29 331 (35) 111 (35) 341 (36) 113 (36)
≥ 30 283 (30) 94 (30) 259 (28) 87 (27)
Menopausal status 0.4272 0.9889
Unknown 31 (3) 10 (3) 32 (3) 12 (4)
Premenopausal 92 (10) 32 (10) 67 (7) 22 (7)
Perimenopausal 112 (12) 38 (12) 134 (14) 46 (14)
Postmenopausal 712 (75) 237 (75) 702 (75) 238 (75)
Ethnic origin 0.1880 0.2208
Other/unknown 52 (5) 24 (8) 81 (9) 35 (11)
White 895 (95) 293 (92) 854 (91) 283 (89)
Parity 0.7134 0.0399
Unknown 1 (0) 1 (0) 4 (1)
Nulliparous 112 (12) 40 (13) 91 (10) 44 (14)
Parous 834 (88) 277 (87) 843 (90) 270 (85)
Tyrer-Cuzick (10 year risk, %
(median, Q1–Q3))
2.74 (2.18–3.58) 2.94 (2.29–3.88) 0.0006 2.67 (2.09–3.55) 2.91 (2.24–4.05) <.0001
Volumetric PD (median, Q1–Q3) 4.90 (3.63–7.19) 5.43 (4.06–8.13) 0.0034 4.79 (3.58–7.01) 5.51 (3.81–7.98) 0.0044
The p values, from likelihood-ratio chi-square tests, indicate whether there are significant difference between cases and controls
HRT hormone replacement therapy, BMI body mass index, Q1 25th percentile, Q3 75th percentile, PD percent density
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was found to be statistically significant for APD6 (M3,
p value = 0.004; M5, p value = 0.003). Since VPD0 in
M5 did not add information to APD6, the final model
for prediction of screen-detected and interval cancers
was based on APD at a threshold level of 6 mm (i.e.
APD6 with additional interaction term). The resulting
standardised odds ratio for APD at the 6 mm threshold
was 1.81 for interval cancers (95% CI = 1.42–2.30) and
1.18 for screen-detected cancers (95% CI = 0.99–1.40).
Discussion
This paper explores the impact of various levels of dens-
ity thresholding on the performance in prediction of
breast cancer using digital mammograms. To achieve
this, a range of threshold levels from 0 to 25 mm were
tested. For VPD, the threshold was varied so that only
dense tissue where heights were greater than a given
value were included to calculate the total dense volume
of the breast. For APD, we counted the number of dense
Fig. 1 Akaike information criteria (AIC) using volumetric and areal percent density in pooled data
Fig. 2 Distribution of volumetric percent density (VPD) and areal percent density (APD) at different thresholds
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pixels above the threshold level and compared this with
the total number of pixels in the breast to derive the
areal PD.
Results from both case-control studies and from the
pooled data confirm that a threshold level of 5 mm or
6 mm, either volumetric or areal, improves cancer risk
prediction compared to original VPD without threshold-
ing. However, the improvement with VPD at the higher
thresholds was relatively small. This is not surprising
given the strong correlation between VPD0 and VPD5
(spearman ρ approximately 0.95 in both studies). On the
other hand, APD at threshold of 6 mm (APD6) achieved
the best results across all models tested, including VPD
and APD at various threshold levels, with ΔAIC = 14.52
for the pooled data compared to VPD0. It is worth not-
ing that APD6 was also highly correlated with VPD0
(spearman ρ approximately 0.90 in both studies), which
is not surprising given both APD and VPD measure rela-
tive dense tissue albeit from a different perspective. In
addition to fixed threshold levels, varying threshold
levels were also examined with the level of threshold
based on a woman’s characteristics such as age, BMI and
breast volume; however, the AIC did not improve, so a
fixed threshold is preferred.
We also explored the impact of thresholding by visua-
lising mammograms after areas with less dense tissue
Fig. 3 Correlation between volumetric percent density with a 0 mm threshold (VPD0), VPD with a 5 mm threshold (VPD5) and areal percent density
with a 6 mm threshold (APD6)
Table 2 Modelling results for the pooled data
Standardised odds ratio (95% CI)
M1 M2 M3 M4 M5
Volumetric PD (0 mm) 1.26 0.46 0.90
(1.15, 1.39) (0.26, 0.82) (0.74, 1.10)
Volumetric PD (5 mm) 1.29 2.72
(1.18, 1.42) (1.56, 4.74)
Areal PD (6 mm) 1.34 1.47
(1.22, 1.47) (1.21, 1.78)
Model fit statistics
AIC 1727.15 1721.25 1712.63 1715.81 1713.50
mC 0.567 0.577 0.577 0.583 0.582
(0.539, 0.596) (0.548, 0.606) (0.549, 0.605) (0.555, 0.611) (0.553, 0.610)
χ2 21.98 27.87 36.49 35.32 37.62
Standardized odds ratio is the change in odds for a standard deviation increase in predictors. Confidence intervals (CI) are presented in parentheses for the
predictors in each model
M model, PD percent density, AIC Akaike information criterion, mC matched concordance index
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were excluded. As illustrated in Fig. 4, thresholding at
5 mm filtered out a large portion of lower-density areas,
and was roughly comparable to Altocumulus presented
by previous research [6]. Further thresholding at higher
levels at 10 and 15 mm seems to exclude too much in-
formation, thus no further improvement in prediction
was observed at these levels. It appears that by introdu-
cing a suitable threshold level (e.g. 5–6 mm), much of
the “noise” presented in the mammograms (including
fine structures with low attenuation) is removed and
hence results in a more predictive PD estimate.
It is also interesting that whilst APD performed much
worse than VPD initially when the level of thresholding
was low, APD became better than VPD when a thresh-
old level of 4 mm or above was applied, as shown in
Fig. 1. This suggests that VPD is relatively insensitive to
the “noise” presented in mammograms compared to
APD, since VPD is essentially a weighted sum (i.e. if all
dense tissue heights were the same then VPD would be
equivalent to APD). However, after exclusion of the
noise component, the weights (dense tissue heights) be-
came less relevant, resulting in APD being a better pre-
dictor. This is interesting because it suggests that once
the density at each point in the mammogram reaches
some threshold, the measures are equally informative in
terms of cancer risk despite local differences in density.
In terms of the biological plausibility for these fin-
dings, the major component of dense breast tissue is
stroma [15], and pathways for breast cancer risk associ-
ated with dense tissue are likely to involve the stromal
cells, extracellular matrix proteins and the epithelial
component. It has also been shown that local density is
associated with the location where cancer would develop
[16]. However, the causal route between dense tissue
and breast cancer is unknown, and research is ongoing
in this important area [15]. For these reasons we do not
Fig. 4 A visual comparison of “density map” using 0–15 mm threshold levels. Traditional volumetric density such as from the Volpara software
uses a 0 mm threshold (no threshold). VPD0, volumetric percent density with a 0 mm threshold; VPD5, VPD with a 5 mm threshold; APD6, areal
percent density with a 6 mm threshold
Table 3 Modelling results for study 1 in which cancers were detected at initial screening
Standardised odds ratio (95% CI)
M1 M2 M3 M4 M5
Volumetric PD (0 mm) 1.25 0.51 0.96
(1.10,1.43) (0.24,1.09) (0.73,1.25)
Volumetric PD (5 mm) 1.28 2.44
(1.13,1.46) (1.16,5.14)
Areal PD (6 mm) 1.31 1.36
(1.15,1.50) (1.05,1.78)
Model fit statistics
AIC 867.80 865.01 862.55 863.87 864.45
mC 0.559 0.564 0.556 0.573 0.560
(0.518, 0.599) (0.524, 0.604) (0.515, 0.595) (0.533, 0.613) (0.519, 0.600)
χ2 10.81 13.60 16.06 16.74 16.16
Standardized odds ratio is the change in odds for a standard deviation increase in predictors. Confidence intervals (CI) are presented in parentheses for the predictors in
each model
M model, PD percent density, AIC Akaike information criterion, mC matched concordance index
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speculate further on how this measure of breast density
might better capture the biological mechanism for risk
due to dense breast tissue. From a measurement accur-
acy point of view, however, an increased threshold may
remove the areas of fat that look slightly grey on the
image, which might reduce measurement error. Another
possible explanation is that setting an appropriate
threshold removes thin sheets or strands of tissue which
have similar attenuation coefficients to glandular tissue,
and exclusion of this type of tissue might contribute to
better density estimation.
Consistent with previous studies [4–6], our results
show that once the APD at the optimal threshold level is
accounted for, conventional VPD0 no longer adds infor-
mation - in fact models with multiple PD measurements
(M4 and M5) performed worse than the model with only
APD6 as a predictor (M3). While the standardised OR
and mC, including those based on the original VPD es-
timated by Volpara (M1), might seem relatively low
compared with some previous studies [6, 9], the results
are broadly consistent with a body of previous research
[4, 17, 18]. For example, Brandt et al. [17] compared
VPD with BI-RADS using a large case-control sample
(1911 cases and 4170 controls) and identified a similar
discriminatory ability for Volpara VPD (AUC = 0.58, 95%
CI 0.56–0.59) as in our study. It is also worth noting that
the studies that have directly compared VPD by Volpara
with established visual-based assessment such as
BI-RADS and Cumulus have shown broadly similar abil-
ity for risk prediction [12, 17, 19], and so differences in
predictive ability between studies might be due to other
characteristics of the data. It is plausible that the predict-
ive ability of a density measure differs across different
sub groups of women and types of cancers, such as
screen-detected and interval cancers as demonstrated here
and by others [18]. This means the predictive ability likely
depends on the composition of the study population, which
may explain some of the differences between studies.
Previous studies have demonstrated that breast density
adds accuracy to established breast cancer risk models
such as the Tyrer-Cuzick and Gail models [20, 21], in-
cluding in combination with single-nucleotide poly-
morphism risk panels [22]. It is therefore expected that
this study will be of clinical importance, as an improved
automated density measure is likely to help identify
women who require additional screening and to help de-
vise a risk-based screening/prevention strategy.
The strength of our approach, compared to previous
studies [4–6], is that the process is fully automated with-
out any human intervention. Also, by using raw (“for
processing”) digital mammograms, differences due to
manufacturers’ proprietary processing algorithms are re-
duced. Our approach, however, would benefit from test-
ing in a wider range of settings. For example, the
majority of women in our datasets were white and par-
ous, so it would be important to validate our approach
amongst other groups of women. Finally, the mammo-
grams employed in our study are generated from a GE
system. Nguyen et al. [5] found that prediction perform-
ance may vary considerably between different mammo-
graphic machines based on visual assessment. It would
be interesting to further explore the impact of threshold-
ing using different systems in which the image proper-
ties may differ, and how the method can be calibrated
for mammograms from different systems and the result-
ing discriminatory power in different settings.
Table 4 Modelling results for study 2 in which cancers were detected after the initial screening
Standardised odds ratio (95% CI)
M1 M2 M3 M4 M5
Volumetric PD (0 mm) 1.27 0.42 0.84
(1.11,1.47) (0.18,0.97) (0.63,1.12)
Volumetric PD (5 mm) 1.31 3.04
(1.14,1.50) (1.32,6.97)
Areal PD (6 mm) 1.37 1.58
(1.19,1.57) (1.20,2.08)
Model fit statistics
AIC 861.35 858.24 851.99 855.87 852.61
mC 0.576 0.590 0.599 0.597 0.605
mC (0.536, 0.616) (0.551, 0.630) (0.559, 0.640) (0.557, 0.636) (0.565, 0.644)
χ2 11.17 14.27 20.52 18.64 21.91
Standardized odds ratio is the change in odds for a standard deviation increase in predictors. Confidence intervals (CI) are presented in parentheses for the predictors in
each model
M model, PD percent density, AIC Akaike information criterion, mC matched concordance index
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Conclusion
This study examined volumetric and areal PDs defined by
various thresholds, and found that APD at 6 mm is the
best risk predictor of breast cancer in two case-control
studies. The results presented in this study confirm find-
ings from previous studies that dense tissue is more im-
portant for predicting breast cancer risk. Unlike previous
studies where thresholding was based on pixel brightness
by visual assessment, the approach adopted in this paper
was based on the height of dense tissue calculated from
volumetric density estimation, which enables our ap-
proach to be fully automated.
Appendix
The number of cases and controls differs from a previ-
ous report that compared density measurements using
the same women. The reasons are as follows. First, the
first case-control study was a subset of one with 317
cases and 952 controls. Three women were excluded
due to linkage errors between mammograms and ques-
tionnaire data. An additional two women were excluded
because the CC view mammograms at the designated
side of the breast (i.e. either left or right CC view) were
unavailable.
The second case-control study originally had 338
cases and 1014 controls: 23 women were excluded be-
cause of unavailability of mammograms at the time of
analysis (either no mammograms were provided for
some women at the given side; or only mediolateral ob-
lique (MLO) views were available but no CC views). A
further 64 women were removed because the side of
cancer (left or right) was unknown. A further 12 con-
trols were removed during conditional logistic regres-
sion because they had no matched cases as a result of
the aforementioned exclusions.
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